With more than a dozen development candidates, Humabs has a broad and varied pipeline of partnered, internal and public health programs. These anti-infective immunotherapy candidates are being developed to treat several viral and bacterial diseases.

Humabs has a successful track record of advancing its leads through the early stages of development. The Company partnered its most advanced programs while still in preclinical stage, and two of these partnered programs have been advanced into clinical development. With its most advanced internal development candidates directed at HBV, RSV/MPV and Zika virus, Humabs has a strong portfolio for future growth.